^
Association details:
| Biomarker: | IDH1 R132C |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma
Excerpt:
...we developed a human PDX model (SS110) from a resected ICC harboring an IDH1 R132C mutation...Established SS110 tumors (passage 2) were allowed to reach ~900 mm3 and then treated with dasatinib for 7 days...dasatinib had only minimal effects on the growth of an IDH WT ICC PDX.
DOI:
10.1158/2159-8290.CD-15-1442
